Stock listing

NASDAQ:PLYX Polaryx Therapeutics, Inc. Stock

Home listing (NASDAQ) of Polaryx Therapeutics, Inc.

Follow Polaryx Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:PLYX

$1.33 USD -0.28 (-17.4%)

Close on Nov 20, 2026

Since Jan 30, 2026 -84.9% · daily closes, Jan 30, 2026 – Nov 20, 2026, adjusted for splits
Day range
$1.30 – $1.56 USDNov 20, 2026
Volume
49,399 sharesNov 20, 2026
Market cap
$66.30M USDAt the close on Nov 20, 2026 · price × 49.85M shares outstanding
Traded on an average day
$74,853 USDMedian day 25,100 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Polaryx Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:PLYX · Home$1.33 USD-0.28 (-17.4%)49,399$1.51$1.56$1.301$1.61Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PLYX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.33-0.28-17.4%$1.51$1.56$1.30149,399
$1.61+0.01+0.6%$1.65$1.68$1.6122,333
$1.60-0.07-4.2%$1.67$1.671$1.5830,656
$1.67-0.10-5.6%$1.75$1.76$1.6714,855
$1.77-0.11-5.9%$1.88$1.88$1.779,213
$1.88-0.07-3.6%$1.91$1.945$1.889,877
$1.95+0.08+4.3%$1.90$1.95$1.907,024
$1.87-0.07-3.6%$1.98$1.98$1.86514,728
$1.94+0.14+7.8%$1.82$1.94$1.8030,646
$1.80+0.06+3.4%$1.74$1.87$1.73823,545
$1.74-0.06-3.3%$1.75$1.80$1.7060,160
$1.80+0.07+4.0%$1.79$1.84$1.7611,120
$1.73-0.02-1.1%$1.725$1.78$1.6924,895
$1.750.000.0%$1.76$1.84$1.7230,241
$1.75-0.11-5.9%$1.86$1.89$1.7532,570
$1.86-0.03-1.6%$1.83$1.89$1.8315,385
$1.89+0.01+0.5%$1.86$1.91$1.8214,704
$1.88+0.06+3.3%$1.83$1.91$1.82214,872
$1.82-0.03-1.6%$1.92$1.92$1.75527,514
$1.85-0.09-4.6%$1.90$1.90$1.8443,000
$1.940.000.0%$1.85$1.99$1.8515,600
$1.94+0.03+1.6%$1.89$1.94$1.8513,300
$1.91-0.01-0.5%$1.87$1.93$1.838,100
$1.92+0.04+2.1%$1.89$1.92$1.8429,300
$1.88-0.07-3.6%$1.92$2.03$1.8719,500
$1.95-0.02-1.0%$1.94$1.97$1.8842,600
$1.97+0.03+1.5%$1.91$2.05$1.9116,600
$1.94-0.07-3.5%$1.98$2.05$1.9114,800
$2.01+0.01+0.5%$1.99$2.01$1.9716,400
$2.000.000.0%$2.00$2.03$1.9811,000
$2.00-0.09-4.3%$2.04$2.04$1.86160,700
$2.09-0.01-0.5%$2.09$2.10$2.0011,400
$2.10+0.03+1.4%$2.07$2.14$2.075,800
$2.07-0.01-0.5%$2.05$2.15$2.0440,100
$2.08+0.06+3.0%$2.03$2.08$1.9820,800
$2.02-0.05-2.4%$2.05$2.06$1.9759,000
$2.070.000.0%$2.05$2.12$2.0214,800
$2.07+0.03+1.5%$2.05$2.08$2.0031,000
$2.04-0.05-2.4%$2.09$2.14$2.0116,500
$2.09-0.05-2.3%$2.11$2.14$2.0713,400
$2.140.000.0%$2.12$2.15$2.0328,100
$2.14-0.01-0.5%$2.19$2.19$2.0454,600
$2.15+0.01+0.5%$2.11$2.15$2.0825,190
$2.14+0.10+4.9%$2.06$2.168$2.0432,086
$2.04-0.10-4.7%$2.09$2.21$2.0281,400
$2.14+0.11+5.4%$2.06$2.14$2.0527,600
$2.03-0.02-1.0%$2.04$2.16$2.0228,000
$2.05+0.03+1.5%$2.06$2.06$1.9817,100
$2.02+0.01+0.5%$2.00$2.04$1.9725,100
$2.01+0.02+1.0%$2.00$2.09$2.0014,500
$1.99-0.09-4.3%$2.08$2.08$1.9917,400
$2.08+0.06+3.0%$2.08$2.12$2.0123,300
$2.02+0.02+1.0%$1.98$2.04$1.9714,300
$2.00+0.01+0.5%$2.00$2.05$1.9039,700
$1.99-0.05-2.5%$2.05$2.07$1.9821,100
$2.04+0.06+3.0%$2.00$2.07$1.9732,800
$1.98-0.03-1.5%$2.01$2.05$1.9386,000
$2.01-0.05-2.4%$2.10$2.12$1.9941,400
$2.06-0.05-2.4%$2.11$2.14$1.9786,300
$2.11+0.02+1.0%$2.09$2.16$2.0467,100
$2.09+0.10+5.0%$2.10$2.10$1.97112,900
$1.99+0.12+6.4%$1.90$2.10$1.90107,100
$1.87-0.20-9.7%$2.08$2.10$1.85285,900
$2.07-0.07-3.3%$2.14$2.15$2.03108,500
$2.14-0.02-0.9%$2.11$2.20$2.0155,600
Ticker
NASDAQ:PLYX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Polaryx Therapeutics, Inc. news

Polaryx Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
18 in the last 12 months · 18 in all · newest Nov 20, 2026 · oldest 2026
Decks
2 decks · latest November 2026

Where Polaryx Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:PLYX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:PLYXBOATSUnited StatesUSD

Valuation

Price/book 8.7× against a median of 2.7×: the highest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$57.86M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
8.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.66

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Polaryx Therapeutics, Inc. · NASDAQ:PLYXUS$66.30MUS$57.86Mn/an/an/a8.7×n/a0.0×1.66
ABIONYX Pharma SA · EURONEXT:ABNXUS$68.36MUS$55.53Mn/a12.4×n/a4.0×−136.6%1.0×n/a
Cingulate Inc. · NASDAQ:CINGUS$67.48MUS$1.21Bn/an/an/a3.3×n/a56.0×1.41
Energenesis Biomedical Co., Ltd. · TWSE:6657US$67.22MUS$47.02Mn/a203×n/a3.1×n/a0.0×n/a
MediciNova, Inc. · NASDAQ:MNOVUS$67.11MUS$38.45Mn/a41.1×n/a1.6×n/a0.0×0.56
Dicot Pharma AB · OMXSTO:DICOTUS$66.56MUS$44.51Mn/an/an/a3.0×n/a0.0×n/a
Cardiff Oncology, Inc. · NASDAQ:CRDFUS$66.34MUS$32.82Mn/a58.7×n/a2.4×n/a0.0×1.32
PMV Pharmaceuticals, Inc. · NASDAQ:PMVPUS$66.17M−US$36.25Mn/an/an/a1.2×n/a0.0×1.43
Gossamer Bio, Inc. · NASDAQ:GOSSUS$65.57MUS$55.23Mn/a0.7×n/an/a−159.5%n/a1.56
Tenaya Therapeutics, Inc. · NASDAQ:TNYAUS$65.32MUS$1.38Mn/a0.5×n/a1.2×n/a0.1×2.42
Atara Biotherapeutics, Inc. · NASDAQ:ATRAUS$64.49MUS$64.14Mn/a16.2×n/an/a−368.6%n/a1.43
Median of the othersUS$66.45MUS$45.76M16.2×2.7×−159.5%0.0×1.43

Forecasts

3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
7.50 USD · Analysts' mean
EPS, year to Dec 2026
-0.18 · 4 analysts

Team and board

Officers

OfficerRole
Alex YangCEO and Chair of the Board
G. Michael LandisChief Financial Officer
Minsu KangVice President, Clinical Development and Regulatory Affairs
Eddy ZhuChief CMC Officer
Shrijay VijayanChief Scientific and Business Development Officer
Will CharltonChief Medical Officer

Board

DirectorRole
Alex YangCEO and Chair of the Board
Charles RyanDirector
Francis A. BraunDirector
Mitchel BergerDirector

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close−5.8%
Q2 2026Aug 13, 2026 · After close+4.0%
Q1 2026May 15, 2026 · Before open−21.7%
Q4 2025Mar 24, 2026 · Before open+16.7%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck33 slidesNovember 2026
Investor Presentation (October 2026)Investor deck33 slidesOctober 2026

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023
Revenue000
Research and development6.27M2.81M2.77M
Selling, general and administrative1.55M1.54M1.01M
Operating income-7.82M-4.35M-3.78M
Income before tax-8.98M-30.4M-3.78M
Net income-8.98M-30.4M-3.78M
Earnings per share, basic-0.20-0.89-0.02
Earnings per share, diluted-0.20-0.89

Balance sheet

LineFY2025FY2024FY2023
Cash and equivalents5.14M4.62M2.00K
Current assets5.17M5.00M2.31M
Total assets5.17M5.00M2.31M
Accounts payable470.0K72.0K473.0K
Current liabilities605.0K289.0K1.04M
Total debt128.0K
Total liabilities605.0K289.0K1.04M
Shareholders' equity4.57M4.71M1.28M
Shares outstanding47.3M41.2M189.4M

Cash flow

LineFY2025FY2024FY2023
Cash from operations-3.94M-2.57M-173.0K
Capital spending000
Free cash flow-3.94M-2.57M-173.0K
Cash from financing4.47M7.19M128.0K
Change in cash522.0K4.62M-45.0K

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportSep 11, 2026Meeting outcomeSEC
8-K · Current reportSep 1, 2026Current reportSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
ARS · Annual report to shareholdersJul 28, 2026Annual reportSEC
DEFA14A · Additional proxy materialJul 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementJul 28, 2026Meeting noticeSEC
S-8 · Registration statement for employee plansJul 24, 2026Offer documentSEC
8-K · Current reportJul 21, 2026Management or board changeSEC
8-K · Current reportJul 17, 2026Current reportSEC
All 36 filings
FilingDateTypeFiled with
4 · Change in ownershipMay 28, 2026Insider tradeSEC
8-K · Current reportMay 28, 2026Material contractSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
10-K · Annual reportMar 23, 2026Annual reportSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
SCHEDULE 13D · Big-stake noticeFeb 5, 2026Big-stake noticeSEC
424B4 · ProspectusFeb 2, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 30, 2026Other filingsSEC
3 · Initial statement of ownershipJan 29, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 29, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 29, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 29, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 29, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 29, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 29, 2026Insider tradeSEC
CERT · Exchange's certificate of listingJan 28, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeJan 27, 2026Other filingsSEC
S-1/A · Registration statement, amendedJan 27, 2026Offer documentSEC
S-1/A · Registration statement, amendedJan 13, 2026Offer documentSEC
S-1 · Registration statementNov 20, 2025Offer documentSEC
C-UOct 31, 2025Other filingsSEC
C-UOct 27, 2025Other filingsSEC
C/AOct 1, 2025Other filingsSEC
DRS/A · Draft registration statement, amendedSep 18, 2025Offer documentSEC
CSep 3, 2025Other filingsSEC
DRS · Draft registration statementAug 5, 2025Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Polaryx Therapeutics, Inc.’s releases · as of Oct 31, 2026

Common shares
49,845,993
Fully diluted
49,845,993

Fully diluted

LineSharesAs of
Common shares49,845,993Oct 31, 2026

Share count over time

CountShares
Oct 31, 202649,845,993

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard1.74M3.5%US$3.61MSep 30, 2026
Geode Capital139K0.28%US$287KSep 30, 2026
State Street68,0040.14%US$141KSep 30, 2026
BlackRock41,0120.08%US$84,895Sep 30, 2026
Hrt Financial LP33,1030.07%US$68,000Sep 30, 2026
Northern Trust27,9870.06%US$57,933Sep 30, 2026
Cerity Partners LLC10,4270.02%US$21,584Sep 30, 2026
Allworth Financial LP7,7270.02%US$15,995Sep 30, 2026
UBS4,355<0.01%US$9,015Sep 30, 2026
Tower Research Capital LLC (TRC)1,855<0.01%US$3,840Sep 30, 2026
All 11 holders
HolderSharesOf the companyValueAs of
Barclays9<0.01%US$19Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.47M2.9%US$3.9MJun 30, 2026
Vanguard Extended Market Index Fund142K0.28%US$378KJun 30, 2026
Fidelity Extended Market Index Fund67,0790.13%US$219KMay 31, 2026
Fidelity Nasdaq Composite Index Fund28,6480.06%US$93,679May 31, 2026
Fidelity Total Market Index Fund26,4500.05%US$86,492May 31, 2026
Vanguard Balanced Index Fund25,9690.05%US$69,078Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund21,8560.04%US$58,137Jun 30, 2026
Fidelity Series Total Market Index Fund19,6050.04%US$64,108May 31, 2026
Total Stock Market Index Trust865<0.01%US$2,301Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Mstone Partners Healthcare Ltd
Director, 10% owner
Buy88,453USD 4.07US$360KMay 27, 2026

Big stakes

StakeStakeSharesDateFiling
Alex Keun Mo Yang48.00%22.7MJan 29, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Francis A Braun III
Other companies: ITG, Inc. (Director · Since at least Jul 1, 2026); Elite Express Holding Inc. (Director · Since at least Aug 20, 2025); SHF Holdings, Inc. (Director · Since at least Aug 7, 2025)
Director · Since at least Jan 29, 2026
Charles Ryan
Other companies: Quince Therapeutics, Inc. (President · Since at least Sep 1, 2023); Neurotrope Inc (Director · Nov 24, 2020 – Dec 1, 2020 · Past)
Director · Since at least Jan 29, 2026
G. Michael Landis
Other companies: Lannett Company Inc (Principal Accounting Officer · Apr 24, 2012 – Jul 1, 2020 · Past)
Chief Financial Officer · Since at least Jan 29, 2026
Alex Keun Mo YangChief Executive Officer, Director · Since at least Jan 29, 2026
Alex YangCEO and Chair of the Board · Since at least Sep 1, 2026
Andrew John OChief Investment Officer · Since at least Jan 29, 2026
Eddy ZhuChief CMC Officer · Since at least Nov 4, 2026
Francis A. BraunDirector · Since at least Feb 5, 2026
Minsu KangVice President, Clinical Development and Regulatory Affairs · Since at least Mar 12, 2026
Mitchel BergerDirector · Since at least Jan 29, 2026
All 13 people
PersonSeat
Shrijay VijayanChief Scientific and Business Development Officer · Since at least Mar 12, 2026
Will CharltonChief Medical Officer · Since Sep 1, 2026 · Appointed, no departure found
Will CharltonChief Medical Officer · Since at least Sep 1, 2026

Open People

Log in to ask 6ix AI your own questions about Polaryx Therapeutics, Inc.